ICD10 code of Agammaglobulinemia and ICD9 code

Agammaglobulinemia, most notably X-linked agammaglobulinemia (XLA), is classified under ICD-10 code D80.0 (Congenital hypogammaglobulinemia) and ICD-9 code 279.04 (Congenital agammaglobulinemia). These codes are used by healthcare providers and insurance systems to track this rare primary immunodeficiency characterized by a near-total lack of protective antibodies.

What is the clinical significance of these codes for Agammaglobulinemia?

In clinical practice, ICD codes for Agammaglobulinemia serve as the standard language for medical billing and epidemiological tracking. While D80.0 is the primary classification for Agammaglobulinemia, clinicians must often specify the underlying genetic cause—such as a mutation in the BTK gene—to ensure patients receive appropriate access to life-saving immunoglobulin replacement therapy. Accurate coding is essential for securing long-term coverage for these necessary treatments.

How does Agammaglobulinemia affect the immune system?

Agammaglobulinemia occurs when the body fails to produce mature B-cells, resulting in a profound deficiency of serum immunoglobulins (IgG, IgA, IgM). Without these antibodies, individuals are highly susceptible to recurrent bacterial infections, particularly in the respiratory and gastrointestinal tracts. The disease typically manifests in early childhood, often after maternal antibody protection wanes around 6 to 9 months of age.

What are the diagnostic markers for Agammaglobulinemia?

Diagnosis of Agammaglobulinemia generally involves a combination of laboratory testing and genetic evaluation. Key diagnostic indicators include:

• Extremely low or absent levels of all major antibody classes (IgG, IgA, IgM).


• A profound reduction or absence of peripheral blood B-cells (CD19+ or CD20+).


• Poor or absent antibody responses to vaccinations.


• Molecular genetic testing confirming a pathogenic variant in the BTK gene for X-linked cases.

Next steps

• Consult an expert clinical immunologist to discuss regular immunoglobulin replacement therapy.


• Connect with the 4 members currently sharing their experiences with Agammaglobulinemia on DiseaseMaps.org to find peer support.


• Contact the Immune Deficiency Foundation (IDF) for specialized educational resources on managing Agammaglobulinemia.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.

References

• National Institutes of Health (NIH) GARD: Agammaglobulinemia


• Orphanet: X-linked agammaglobulinemia (ORPHA:602)


• Online Mendelian Inheritance in Man (OMIM): #300300 (Agammaglobulinemia, X-linked)


• Immune Deficiency Foundation (IDF): Understanding Primary Immunodeficiency